Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Advanced BRCA-mutated Breast Cancers
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Planned End Date changed from 1 Jan 2021 to 30 Jan 2023.
- 07 Jun 2017 Planned primary completion date changed from 1 Jan 2019 to 30 Jan 2018.
- 07 Jun 2017 Status changed from not yet recruiting to recruiting.